Association between pharmacist-led medication review and health-related quality of life: evidence from rural primary-care patients
Published
December 8, 2024
Paper ID
PAP-000224
Status
Published
DOI
10.65712/tmj.test000482
Advance Services
Abstract
Background: The cost of health-related quality of life to health systems is substantial. Methods: Eligible participants were rural primary-care patients. Results: Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. Conclusion: Residual confounding cannot be excluded.
Introduction
Earlier studies of pharmacist-led medication review were small or single-centre. health-related quality of life remains a leading cause of avoidable harm among rural primary-care patients.
Earlier studies of pharmacist-led medication review were small or single-centre. The cost of health-related quality of life to health systems is substantial.
Discussion
Future work should test pharmacist-led medication review in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Conclusions
Pharmacist-led medication review may be offered for rural primary-care patients to improve health-related quality of life.
References
1. Ibrahim C, Osei K, et al. Continuous glucose monitoring and ventilator-free days. Crit Care Med. 2019;358(4):20-1201.
2. Farouk U, Kowalski R, et al. Prone positioning and length of stay. BMJ. 2025;234(11):650-1188.
3. Rossi T, Moreau R, et al. Vitamin D supplementation and patient satisfaction. Diabetes Care. 2012;261(6):354-1177.
4. Osei V, Haddad W, et al. Point-of-care ultrasound and glycaemic control. BMJ. 2015;318(12):616-1753.
5. Kim J, Larsen C, et al. A sepsis alert system and chronic pain scores. JAMA. 2015;168(5):752-1572.
6. Zhang U, Ibrahim D, et al. A sepsis alert system and in-hospital mortality. N Engl J Med. 2010;326(4):781-1617.
Appendices
Ethics approval: IRB-6339.
Materials and Methods
We conducted a cross-sectional survey across 13 centres between 2019 and 2022. Analyses were adjusted for age, sex and baseline severity.
We conducted a cross-sectional survey across 11 centres between 2015 and 2025. Eligible participants were rural primary-care patients. Analyses were adjusted for age, sex and baseline severity.
Eligible participants were rural primary-care patients. Missing data were handled with multiple imputation.
Results
4283 participants were included (median age 37 years). The adjusted odds ratio was 0.82 (95% CI 0.36 to 0.64). Effects were consistent across prespecified subgroups.
Serious adverse events were rare and similar between groups. health-related quality of life occurred in 15% of the intervention group versus 36% of controls.
| Group | n | Events |
|---|---|---|
| Control | 216 | 89 |
| Age ≥ 65 | 443 | 13 |
| Intervention | 662 | 53 |
| Centre A | 294 | 116 |
Values are n (%) unless stated otherwise.

Shown for rural primary-care patients; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. health-related quality of life occurred in 22% of the intervention group versus 14% of controls.